Cargando…

The Immunotherapy Landscape in Adrenocortical Cancer

SIMPLE SUMMARY: Adrenocortical carcinoma is a rare and life-threatening cancer originating from the adrenal glands. Although aggressive surgical interventions may cure this cancer when detected at early stages, treatments for advanced or metastatic disease are limited and often unable to shrink or c...

Descripción completa

Detalles Bibliográficos
Autores principales: Pegna, Guillaume J., Roper, Nitin, Kaplan, Rosandra N., Bergsland, Emily, Kiseljak-Vassiliades, Katja, Habra, Mouhammed Amir, Pommier, Yves, Del Rivero, Jaydira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199088/
https://www.ncbi.nlm.nih.gov/pubmed/34071333
http://dx.doi.org/10.3390/cancers13112660
_version_ 1783707294008082432
author Pegna, Guillaume J.
Roper, Nitin
Kaplan, Rosandra N.
Bergsland, Emily
Kiseljak-Vassiliades, Katja
Habra, Mouhammed Amir
Pommier, Yves
Del Rivero, Jaydira
author_facet Pegna, Guillaume J.
Roper, Nitin
Kaplan, Rosandra N.
Bergsland, Emily
Kiseljak-Vassiliades, Katja
Habra, Mouhammed Amir
Pommier, Yves
Del Rivero, Jaydira
author_sort Pegna, Guillaume J.
collection PubMed
description SIMPLE SUMMARY: Adrenocortical carcinoma is a rare and life-threatening cancer originating from the adrenal glands. Although aggressive surgical interventions may cure this cancer when detected at early stages, treatments for advanced or metastatic disease are limited and often unable to shrink or control the growth of this tumor. Research into new treatments is needed for adrenal cortical carcinoma and other rare cancers. For cancers and other medical conditions, new therapies can be tested through clinical trials, in which patients are treated with new medications or innovative medication combinations. Among these novel and innovative treatments are immunotherapies. These therapies are playing an increasingly important role in the treatment of multiple different cancers. This article focuses on the various immunotherapies that have been, currently are, or will be tested in clinical trials for the treatment of adrenocortical carcinoma. ABSTRACT: Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal gland that is frequently associated with excess production of adrenal hormones. Although surgical resection may be curative in early-stage disease, few effective therapeutic options exist in the inoperable advanced or metastatic setting. Immunotherapies, inclusive of a broad array of immune-activating and immune-modulating antineoplastic agents, have demonstrated clinical benefit in a wide range of solid and hematologic malignancies. Due to the broad activity across multiple cancer types, there is significant interest in testing these agents in rare tumors, including ACC. Multiple clinical trials evaluating immunotherapies for the treatment of ACC have been conducted, and many more are ongoing or planned. Immunotherapies that have been evaluated in clinical trials for ACC include the immune checkpoint inhibitors pembrolizumab, nivolumab, and avelumab. Other immunotherapies that have been evaluated include the monoclonal antibodies figitumumab and cixutumumab directed against the ACC-expressed insulin-like growth factor 1 (IGF-1) receptor, the recombinant cytotoxin interleukin-13-pseudomonas exotoxin A, and autologous tumor lysate dendritic cell vaccine. These agents have shown modest clinical activity, although nonzero in the case of the immune checkpoint inhibitors. Clinical trials are ongoing to evaluate whether this clinical activity may be augmented through combinations with other immune-acting agents or targeted therapies.
format Online
Article
Text
id pubmed-8199088
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81990882021-06-14 The Immunotherapy Landscape in Adrenocortical Cancer Pegna, Guillaume J. Roper, Nitin Kaplan, Rosandra N. Bergsland, Emily Kiseljak-Vassiliades, Katja Habra, Mouhammed Amir Pommier, Yves Del Rivero, Jaydira Cancers (Basel) Review SIMPLE SUMMARY: Adrenocortical carcinoma is a rare and life-threatening cancer originating from the adrenal glands. Although aggressive surgical interventions may cure this cancer when detected at early stages, treatments for advanced or metastatic disease are limited and often unable to shrink or control the growth of this tumor. Research into new treatments is needed for adrenal cortical carcinoma and other rare cancers. For cancers and other medical conditions, new therapies can be tested through clinical trials, in which patients are treated with new medications or innovative medication combinations. Among these novel and innovative treatments are immunotherapies. These therapies are playing an increasingly important role in the treatment of multiple different cancers. This article focuses on the various immunotherapies that have been, currently are, or will be tested in clinical trials for the treatment of adrenocortical carcinoma. ABSTRACT: Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal gland that is frequently associated with excess production of adrenal hormones. Although surgical resection may be curative in early-stage disease, few effective therapeutic options exist in the inoperable advanced or metastatic setting. Immunotherapies, inclusive of a broad array of immune-activating and immune-modulating antineoplastic agents, have demonstrated clinical benefit in a wide range of solid and hematologic malignancies. Due to the broad activity across multiple cancer types, there is significant interest in testing these agents in rare tumors, including ACC. Multiple clinical trials evaluating immunotherapies for the treatment of ACC have been conducted, and many more are ongoing or planned. Immunotherapies that have been evaluated in clinical trials for ACC include the immune checkpoint inhibitors pembrolizumab, nivolumab, and avelumab. Other immunotherapies that have been evaluated include the monoclonal antibodies figitumumab and cixutumumab directed against the ACC-expressed insulin-like growth factor 1 (IGF-1) receptor, the recombinant cytotoxin interleukin-13-pseudomonas exotoxin A, and autologous tumor lysate dendritic cell vaccine. These agents have shown modest clinical activity, although nonzero in the case of the immune checkpoint inhibitors. Clinical trials are ongoing to evaluate whether this clinical activity may be augmented through combinations with other immune-acting agents or targeted therapies. MDPI 2021-05-28 /pmc/articles/PMC8199088/ /pubmed/34071333 http://dx.doi.org/10.3390/cancers13112660 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pegna, Guillaume J.
Roper, Nitin
Kaplan, Rosandra N.
Bergsland, Emily
Kiseljak-Vassiliades, Katja
Habra, Mouhammed Amir
Pommier, Yves
Del Rivero, Jaydira
The Immunotherapy Landscape in Adrenocortical Cancer
title The Immunotherapy Landscape in Adrenocortical Cancer
title_full The Immunotherapy Landscape in Adrenocortical Cancer
title_fullStr The Immunotherapy Landscape in Adrenocortical Cancer
title_full_unstemmed The Immunotherapy Landscape in Adrenocortical Cancer
title_short The Immunotherapy Landscape in Adrenocortical Cancer
title_sort immunotherapy landscape in adrenocortical cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199088/
https://www.ncbi.nlm.nih.gov/pubmed/34071333
http://dx.doi.org/10.3390/cancers13112660
work_keys_str_mv AT pegnaguillaumej theimmunotherapylandscapeinadrenocorticalcancer
AT ropernitin theimmunotherapylandscapeinadrenocorticalcancer
AT kaplanrosandran theimmunotherapylandscapeinadrenocorticalcancer
AT bergslandemily theimmunotherapylandscapeinadrenocorticalcancer
AT kiseljakvassiliadeskatja theimmunotherapylandscapeinadrenocorticalcancer
AT habramouhammedamir theimmunotherapylandscapeinadrenocorticalcancer
AT pommieryves theimmunotherapylandscapeinadrenocorticalcancer
AT delriverojaydira theimmunotherapylandscapeinadrenocorticalcancer
AT pegnaguillaumej immunotherapylandscapeinadrenocorticalcancer
AT ropernitin immunotherapylandscapeinadrenocorticalcancer
AT kaplanrosandran immunotherapylandscapeinadrenocorticalcancer
AT bergslandemily immunotherapylandscapeinadrenocorticalcancer
AT kiseljakvassiliadeskatja immunotherapylandscapeinadrenocorticalcancer
AT habramouhammedamir immunotherapylandscapeinadrenocorticalcancer
AT pommieryves immunotherapylandscapeinadrenocorticalcancer
AT delriverojaydira immunotherapylandscapeinadrenocorticalcancer